↓ Skip to main content

New Treatment Modalities for Neovascular Age-Related Macular Degeneration

Overview of attention for article published in Asia Pacific Journal of Ophthalmology, January 2017
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#16 of 115)
  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
New Treatment Modalities for Neovascular Age-Related Macular Degeneration
Published in
Asia Pacific Journal of Ophthalmology, January 2017
DOI 10.22608/apo.2017258
Pubmed ID
Abstract

Age-related macular degeneration (AMD) is considered one of the main causes of severe vision loss in older adults. The neovascular form (nAMD) is an advanced stage, which is responsible for the most severe vision loss. Vascular endothelial growth factor (VEGF) is at present the main factor that leads to the development of a neovascular membrane and the increased leakage from the membrane to the retina. At present, anti-VEGF therapy is the only treatment that achieves vision gains in many patients and halts progression in most of them. VEGF blockade can be achieved with several molecules and various treatment regimens, which have been studied with excellent results. Unfortunately, real-world data has shown to be far less efficacious than clinical trials. This gap between clinical trials and real-world results is an unmet medical need that supports the necessity of new treatment modalities for nAMD. Of the various treatments being studied, anti-VEGFs of higher efficacy and longer durability are those more advanced in their development. Brolucizumab and abicipar pegol are 2 new anti-VEGF drugs that had positive results in phase 2 studies and are being tested in phase 3 trials at present. Other promising therapies are antiangiopoietin 2 molecules, which are in phase 2 development. At earlier stages of development but with promising results are squalamine, anti-VEGF-C and -D, and gene therapy. The future will give retina specialists a broad armamentarium with which patients may achieve high visual gains for the long term with a low treatment burden.

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 50 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 16%
Student > Ph. D. Student 6 12%
Researcher 5 10%
Student > Master 5 10%
Other 4 8%
Other 6 12%
Unknown 16 32%
Readers by discipline Count As %
Medicine and Dentistry 21 42%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Biochemistry, Genetics and Molecular Biology 4 8%
Business, Management and Accounting 1 2%
Nursing and Health Professions 1 2%
Other 3 6%
Unknown 16 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2018.
All research outputs
#3,884,199
of 13,137,393 outputs
Outputs from Asia Pacific Journal of Ophthalmology
#16
of 115 outputs
Outputs of similar age
#121,640
of 346,400 outputs
Outputs of similar age from Asia Pacific Journal of Ophthalmology
#3
of 15 outputs
Altmetric has tracked 13,137,393 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 115 research outputs from this source. They receive a mean Attention Score of 2.3. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,400 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.